Nasdaq
$55.95▼ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.81BShares out 1.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.6After-hours26.10.07 05:228-KKey event#●●●#●●●
BIOMARIN PHARMACEUTICAL INCBullish
BioMarin expects to incur approximately $283 million in acquired in-process research and development (IPR&D) charges in the third quarter of 2026 related to its acquisition of Alesta Therapeutics. These charges, along with ongoing operating expenses, are projected to negatively impact both GAAP and Non-GAAP diluted EPS by approximately $1.50 for the third quarter and $1.55 for the full year 2026.…more
$55.95-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 05:234Ownership
BIOMARIN PHARMACEUTICAL INC
Gregory R. Friberg, an insider at BioMarin Pharmaceutical Inc., filed a Form 4 report regarding changes in beneficial ownership of securities as of September 30, 2026. This filing documents the insider's equity transaction activity.…more
$55.95-0.03%vs prev closeView filingShare - 9.30After-hours26.10.01 05:158-KKey event
BIOMARIN PHARMACEUTICAL INC
BioMarin has entered into a settlement and license agreement with Ascendis Pharma, resulting in the dismissal of all pending litigation between the parties. Under the agreement, BioMarin will receive royalties of 20% on U.S. net sales and 18% on net sales in the EU, Brazil, and South Korea for licensed products through May 2030.…more
$55.95-0.03%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 22:09#●●●#●●●
BioMarin to Present New Clinical Data for VOXZOGO at ASBMR Meeting
BioMarin will present new clinical data for its achondroplasia treatment, VOXZOGO, and other investigational therapies at the American Society for Bone and Mineral Research meeting. The company is currently seeking FDA approval for VOXZOGO to treat hypochondroplasia, with potential for future label expansion.…more
$55.95-0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6After-hours26.10.07 05:31
●●●●●●●● ●●●●● ●●●●●●
BioMarin Pharmaceutical anticipates $283 million in pre-tax charges for Q3 related to the Alesta acquisition. This is expected to negatively impact both GAAP and non-GAAP diluted EPS for the third quarter and fiscal year 2026.…more
$55.95-0.03%vs prev closeShareBenzinga - 10.2Regular26.10.03 00:01
●●●●●●●● ●●●●● ●●●●●●
BioMarin announced new efficacy and safety data for its POMBILITI and OPFOLDA combination therapy at the World Muscle Society Congress. No new safety signals were identified, reinforcing the clinical profile of the treatment for late-onset Pompe disease.…more
$55.95-0.03%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report